{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:26:15Z","timestamp":1778631975947,"version":"3.51.4"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0310101, JP21fk0310101"],"award-info":[{"award-number":["JP20fk0310101, JP21fk0310101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background &amp; aims<\/jats:title>\n<jats:p>There is insufficient data on the clinical course of chronic hepatitis B (CHB) patients in the immune-tolerant (IT) and immune-clearance, inactive (IC) phases over a long follow-up period.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Design<\/jats:title>\n<jats:p>We enrolled 466 CHB patients from our historical cohort, including 56 IT+MA\u3000 (mildly active), 134 IC, 230 with chronic active hepatitis (CH) and 46 with liver cirrhosis (LC), who were categorized to each phase by at least one year of follow-up period from the first visit to our hospital. We investigated long-term risks, and their factors, of developing hepatocellular carcinoma (HCC), and the transition between the clinical phases, especially in the IT+MA and IC groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of the 56 patients in the IT+MA group, 27 remained the IT+MA phase, but 29 transitioned to the CH phase and started nucleot(s)ide analogue (NA) treatment during the follow-up period. Meanwhile, of the 134 patients in the IC group, only 5 started NA treatment after progressing to the CH phase. The development of HCC from the IT+MA, IC, CH, and LC groups was observed in 2, 2, 9, and 20 cases, respectively. The cumulative incidence rates of developing HCC in the IT+MA, IC, CH, and LC groups were 9.9, 1.8, 3.0, and 53.1% at 10 years. In the CH and LC group, patients who developed HCC were older, had higher levels of FIB-4 index, M2BPGi, HBcrAg and AFP, and had lower levels of albumin and platelet counts. In CH patients, FIB-4 index levels were elevated at the diagnosis of HCC compared to baseline, whereas these decreased during the follow-up period in non-HCC patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>HCC occurred at a certain rate among patients in the IT+MA and IC groups. Careful follow-up is required for CH patients with higher levels of FIB-4 index and\/or M2BPGi because of the high incidence of HCC development. (299 words)<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0261878","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T19:00:54Z","timestamp":1640718054000},"page":"e0261878","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection"],"prefix":"10.1371","volume":"16","author":[{"given":"Takanori","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Nagura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Iio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6966","authenticated-orcid":true,"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"pone.0261878.ref001","unstructured":"Organization WH. World Health Organization factsheets for chronic hepatitis B (Last updated 18 July 2019)."},{"issue":"1","key":"pone.0261878.ref002","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/0003-4819-147-1-200707030-00010","article-title":"The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points","volume":"147","author":"CL Lai","year":"2007","journal-title":"Ann Intern Med"},{"issue":"6","key":"pone.0261878.ref003","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection","volume":"47","author":"M Lai","year":"2007","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0261878.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"SK Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"pone.0261878.ref005","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"NA Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"pone.0261878.ref006","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"YS Hsu","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"pone.0261878.ref007","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jvh.12370","article-title":"Treating Immune-tolerant Hepatitis B","volume":"22","author":"TC Tseng","year":"2015","journal-title":"J Viral Hepat"},{"issue":"5","key":"pone.0261878.ref008","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"GA Kim","year":"2018","journal-title":"Gut"},{"issue":"1","key":"pone.0261878.ref009","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41598-019-39043-2","article-title":"Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals","volume":"9","author":"HW Lee","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0261878.ref010","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/0016-5085(87)90613-5","article-title":"Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection","volume":"92","author":"AS Lok","year":"1987","journal-title":"Gastroenterology"},{"issue":"9","key":"pone.0261878.ref011","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"JJ Sung","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"pone.0261878.ref012","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"T Hosaka","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"pone.0261878.ref013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jiy391","article-title":"Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study","volume":"219","author":"MH Nguyen","year":"2019","journal-title":"J Infect Dis"},{"issue":"5","key":"pone.0261878.ref014","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.gastro.2013.02.002","article-title":"Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment","volume":"144","author":"GL Wong","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"pone.0261878.ref015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7150\/jca.16523","article-title":"Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir","volume":"8","author":"H Nishikawa","year":"2017","journal-title":"J Cancer"},{"issue":"7","key":"pone.0261878.ref016","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00535-017-1424-0","article-title":"High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues","volume":"53","author":"N Shinkai","year":"2018","journal-title":"J Gastroenterol"},{"issue":"1","key":"pone.0261878.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hepr.12108","article-title":"Guidelines for avoiding risks resulting from discontinuation of nucleoside\/nucleotide analogs in patients with chronic hepatitis B","volume":"44","author":"E Tanaka","year":"2014","journal-title":"Hepatol Res"},{"issue":"8","key":"pone.0261878.ref018","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/hepr.13504","article-title":"Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"issue":"1","key":"pone.0261878.ref019","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27382","article-title":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis","volume":"61","author":"G Xiao","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"pone.0261878.ref020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2019EZR\u2019 for medical statistics","volume":"48","author":"Y. Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"pone.0261878.ref021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.20760","article-title":"Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine","volume":"42","author":"GV Papatheodoridis","year":"2005","journal-title":"Hepatology"},{"issue":"10","key":"pone.0261878.ref022","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"VW Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"pone.0261878.ref023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-981-10-5765-6_2","article-title":"Hepatitis B Virus-Associated Hepatocellular Carcinoma","volume":"1018","author":"Y. Xie","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"pone.0261878.ref024","first-page":"511","article-title":"Immune tolerant hepatitis B: a clinical dilemma","volume":"7","author":"TT Tran","year":"2011","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"Suppl 1","key":"pone.0261878.ref025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/liv.12996","article-title":"HBV: Do I treat my immunotolerant patients?","volume":"36","author":"J Vlachogiannakos","year":"2016","journal-title":"Liver Int"},{"issue":"5","key":"pone.0261878.ref026","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"M Kumar","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"pone.0261878.ref027","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-118-3-199302010-00006","article-title":"The natural history of asymptomatic hepatitis B surface antigen carriers","volume":"118","author":"R de Franchis","year":"1993","journal-title":"Ann Intern Med"},{"issue":"6","key":"pone.0261878.ref028","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/1751-2980.12051","article-title":"Hepatitis B inactive carriers: clinical course and outcomes","volume":"14","author":"MJ Tong","year":"2013","journal-title":"J Dig Dis"},{"issue":"4","key":"pone.0261878.ref029","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"RP Perrillo","year":"2001","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0261878.ref030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"A Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"pone.0261878.ref031","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/hep.27305","article-title":"Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients","volume":"60","author":"K Yamasaki","year":"2014","journal-title":"Hepatology"},{"issue":"7","key":"pone.0261878.ref032","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00535-014-1007-2","article-title":"Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease","volume":"50","author":"M Abe","year":"2015","journal-title":"J Gastroenterol"},{"issue":"1","key":"pone.0261878.ref033","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/liv.13188","article-title":"Serum WFA(+) -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection","volume":"37","author":"X Zou","year":"2017","journal-title":"Liver Int"},{"issue":"6","key":"pone.0261878.ref034","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/liv.13341","article-title":"Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development","volume":"37","author":"SU Kim","year":"2017","journal-title":"Liver Int"},{"issue":"3","key":"pone.0261878.ref035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis","volume":"58","author":"T Kumada","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0261878.ref036","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/apt.15108","article-title":"Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues","volume":"49","author":"T Hosaka","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"pone.0261878.ref037","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","article-title":"The clinical implications of hepatitis B virus genotype: Recent advances","volume":"26","author":"CL Lin","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"pone.0261878.ref038","doi-asserted-by":"crossref","DOI":"10.1016\/j.cld.2011.03.006","article-title":"The global epidemiology of hepatocellular carcinoma: present and future","volume":"15","author":"KA McGlynn","year":"2011","journal-title":"Clin Liver Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T19:01:21Z","timestamp":1640718081000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261878"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261878","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}